<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141096</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Clinical outcomes of 2 pediatric patients with Gaucher's disease in enzyme replacement therapy for 9 years</dc:title>
<dc:description xml:lang="en">We report two cases of type 1 Gaucher's disease in childhood and their outcomes after 9 years of enzyme replacement therapy. The first case concerns a 6-year-old boy who was diagnosed with Gaucher's disease after developing petechial exanthema, thrombocytopenia, anemia and hepatosplenomegaly, coinciding with chickenpox. The second case involves a 9-year-old girl who was referred to our unit. She had hepatosplenomegaly since 4-month-old and sub sequently developed thrombocytopenia. Both patients have the N370S/L444P mutation. Enzyme replacement therapy was started with 60U/kg imiglucerase every 2 weeks at the age of 6 and 9 years, respectively. In both patients, the therapeutic goals were achieved and maintained throughout treatment with a dose of 30U/kg (AU)</dc:description>
<dc:creator>Quijada Fraile, Pilar</dc:creator>
<dc:creator>Martín Hernández, Elena</dc:creator>
<dc:creator>García-Silva, María Teresa</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Presentamos 2 casos clínicos de enfermedad de Gaucher tipo 1 en la infancia y su evolución tras 9 años de tratamiento de sustitución enzimática (TSE). El caso 1 es un niño de 6 años diagnosticado de enfermedad de Gaucher tras haber presentado, coincidiendo con la varicela, un exantema petequial, trombocitopenia, anemia y hepatoesplenomegalia. El caso 2 es una niña remitida a la consulta a los 9 años de edad. Presentaba hepatoesplenomegalia desde los 4 meses y, posteriormente, comenzó con trombocitopenia. Los 2 presentan la mutación N370S/L444P. Se inició TSE con imiglucerasa a 60U/kg cada 2 semanas a los 6 y 9 años, respectivamente. En ambos se alcanzaron los objetivos terapéuticos y se han mantenido a lo largo del tratamiento con una dosis de 30U/kg (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);137(supl.1): 43-45, sept. 2011. graf</dc:source>
<dc:identifier>ibc-141096</dc:identifier>
<dc:title xml:lang="es">Evolución clínica de dos pacientes pediátricos con enfermedad de Gaucher en tratamiento enzimático durante 9 años</dc:title>
<dc:subject>^d5916^s22033</dc:subject>
<dc:subject>^d5916^s22057</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d53690</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d6107^s22073</dc:subject>
<dc:subject>^d14384</dc:subject>
<dc:type>article</dc:type>
<dc:date>201109</dc:date>
</metadata>
</record>
</ibecs-document>
